Form 4: Y-mAbs Therapeutics Director Hamill Laura Reports Stock and Option Transactions

Director Laura Hamill reports acquisition of restricted stock units and stock options in Y-mAbs Therapeutics.

Summary

• On June 11, 2024, Laura Hamill, a director of Y-mAbs Therapeutics, reported transactions involving the company's securities.
• Hamill acquired 3,495 restricted stock units (RSUs) and disposed of 0 shares.
• Following the transaction, Hamill beneficially owns 5,825 shares of common stock.
• Hamill also acquired 14,545 stock options with an exercise price of $12.01, vesting monthly until June 11, 2025, and expiring on June 11, 2034.
• These transactions were made pursuant to the Issuer's 2018 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitive.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a continued service requirement for the reporting person.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry as part of executive compensation packages. These transactions are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the insider transactions as an indicator of management's confidence in the company.
• Employees who are also granted stock options or RSUs may be motivated by the potential for future gains.

Key Dates